Raynaud's Disease Clinical Trial
Official title:
A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that symptomatic patients experience relief of pain and healing of ulcerations with minimal adverse effects when treated with botulinum toxin type A (Btx-A) injections for Raynaud's phenomenon. The proposed study is the first clinical trial and prospective study designed to document whether or not 1) Btx-A injection relieves pain in a patient's hand affected with Raynaud's disease better than a placebo within 28 days of injection, and 2) Btx-A injection relieves pain associated with Raynaud's disease for longer than 28 days, improving patients' quality of life. Through this study we intend to further determine the effect of injected Btx-A on relieving chronic pain and ulcerations to the ischemic hand while characterizing the patients for whom this treatment is most effective.
PROJECT SUMMARY OVERVIEW: Treating patients with Raynaud's phenomenon who have chronic pain
and ulcerations is extremely challenging. Pharmacologic vasodilators and surgical
sympathectomies offer variable benefits. Case reports, small retrospective outcomes studies,
and our previous work documenting symptomatic patients treated with botulinum toxin type A
(Btx-A) injections for Raynaud's phenomenon have demonstrated relief of pain and healing of
ulcerations with minimal adverse effects. We propose to conduct the first clinical trial and
prospective study documenting the efficacy of this novel treatment modality.
STUDY AIMS: The aims of this proposal are to 1) examine the short-term efficacy of Btx-A
injection compared to placebo in treating pain associated with digit ischemia due to
Raynaud's disease, and 2) describe the long-term efficacy of Btx-A injection in treating pain
associated with digit ischemia due to Raynaud's disease by measuring patient satisfaction and
quality of life changes over time.
APPROACH: Two groups of patients will be enrolled: Group 1 will consist of patients with
primary Raynaud's disease (n=20) and Group 2 of patients with secondary Raynaud's (n=20).
Comparisons between treatment (Btx) and placebo (saline) will occur during the first 28 days
to determine Btx-A's short-term efficacy. Follow-up visits will occur at Days 7 and 28.
Post-assessment on Day 28 marks the beginning of the longitudinal observational study of
patient outcomes. Placebo will no longer be used and patients still suffering from pain will
be eligible for additional Btx-A injections. Patients may receive up to 4 injections of Btx-A
during the 1-year study period if pain or ulcerations recur. During the study period
participants will be followed to collect data on pain-free intervals, ulcer healing,
subsequent treatment choices, patient satisfaction, and changes in quality of life and hand
function. Group comparisons will be made to analyze results. Further stratifications for data
analysis will be made as enrollment numbers allow to control for additional demographic and
disease variables. Quality-adjusted life-years will be calculated to help determine the
societal and individual cost of this treatment.
HYPOTHESIS: We hypothesize that 1) Btx-A injection relieves ischemic pain associated with
Raynaud's disease better than a placebo within 28 days of injection, and 2) Btx-A injection
relieves ischemic pain associated with Raynaud's disease for longer than 28 days, improving
patients' quality of life. Through this study we intend to further elucidate the efficacy of
injected Btx-A on relieving chronic pain and ulcerations to the ischemic hand while
characterizing the patients for whom this treatment is most effective. This data will help us
to apply for national funding to become the coordinating center for a multi-center clinical
trial. The results of this research have enormous potential to impact millions of patients
who suffer with Raynaud's phenomenon.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00000530 -
Raynaud's Treatment Study (RTS)
|
Phase 3 | |
| Completed |
NCT00048776 -
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
|
Phase 4 | |
| Completed |
NCT00048763 -
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
|
Phase 4 | |
| Enrolling by invitation |
NCT02615964 -
Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
|
N/A | |
| Completed |
NCT00480753 -
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
|
Phase 2 | |
| Completed |
NCT02396238 -
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
|
N/A | |
| Completed |
NCT00351117 -
St. John's Wort in the Treatment of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00528242 -
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
|
Phase 2 | |
| Completed |
NCT00378521 -
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
|
Phase 2 | |
| Completed |
NCT02683408 -
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
|
N/A | |
| Active, not recruiting |
NCT00577304 -
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00419419 -
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT00266669 -
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
|
Phase 3 | |
| Completed |
NCT01090492 -
PF-00489791 For The Treatment Of Raynaud's
|
Phase 2 |